Tag: Parvus

 Parvus Therapeutics, a biopharmaceutical company developing Navacim™ platform-based disease-specific immunoregulator therapeutics to treat autoimmune diseases by activating endogenous generation of disease-specific regulatory T cells (Tregs) without impairing normal immune system function, today announced an agreement with National Resilience, Inc. (Resilience), for the tech transfer, scale-up and GMP manufacturing of PVT201, Parvus’ lead NavacimTM drug candidate being developed to treat Primary Biliary Cholangitis. “Our collaboration with Resilience, a world class partner with facilities and expertise well matched to the Navacim manufacturing process, de-risks our CMC activities and our overall IND enabling program,” stated Peter Strumph, CEO. “Recent progress by Parvus research ... Read more